Estimating viral titres in solutions with low viral loads

Biologicals

Volumn 39, Issue 4, 2011, Pages 224-230

  Brownie, C ^a   Statt, J ^b   Bauman, P ^b   Buczynski, G ^b   Skjolaas, K ^c   Lee, D ^b   Hotta, J ^b   Roth, N J ^b  

^a Statistical Consultant   (United States)

^b Talecris Biotherapeutics Inc   (United States)

^c Regulatory Affairs Talecris Biotherapeutics   (United States)

Author keywords

Maximum likelihood; Most probable number; Single hit Poisson model; Spearman K rber; TCID50 assay; Virus titre

Indexed keywords

ACCURACY; ARTICLE; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; HOST RANGE; INTERMETHOD COMPARISON; MATHEMATICAL ANALYSIS; MAXIMUM LIKELIHOOD METHOD; NONHUMAN; POISSON DISTRIBUTION; PRIORITY JOURNAL; SPEARMAN KARBER METHOD; VIRUS CONCENTRATION; VIRUS CULTURE; VIRUS INFECTIVITY; VIRUS LOAD; VIRUS TITRE;

ANIMALS; CYTOPATHOGENIC EFFECT, VIRAL; HUMANS; POISSON DISTRIBUTION; SOLUTIONS; VIRAL LOAD;

ANIMALIA;

EID: 79961207115     PISSN: 10451056     EISSN: 10958320     Source Type: Journal    
DOI: 10.1016/j.biologicals.2011.06.007     Document Type: Article

References (16)

1. Note for guidance on virus validation studies: the design, contribution and interpretation of studies validating the inactivation and removal of viruses, CPMP/BWP/268/95 final version 2 1996, Committee for Proprietary Medicinal Products.
2. Note for guidance on plasma-derived medicinal products, CPMP/BWP/269/95, rev. 3, London 2001, Committee for Proprietary Medicinal Products.
3. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use (ICH). Q5A Viral safety evaluation of biotechnology products derived from cell lines of human or animal origin, 1998.
4. Announcement on the marketing authorization on medicinal products. Requirements of validation studies for demonstrating the virus safety of medicinal products derived from human blood or plasma. Fed Gaz 1994, 84. Federal Health Agency and the Paul Ehrlich Institute for Sera and Vaccines, 4 May 1994.
5. Macken C. Design and analysis of serial limiting dilution assays with small sample sizes. J Immunol Methods 1999, 222:13-29.
6. LaBarre D.A., Lowy R.J. Improvements in methods for calculating virus titer estimates from TCID50 and plaque assays. J Virol Methods 2001, 96:107-126.
7. Kundi M. One-hit models for virus inactivation studies. Antivir Res 1999, 41:145-152.
8. Myers L.E., McQuay L.J., Hollinger B. Dilution assay statistics. J Clin Microbiol 1994, 32:732-739.
9. Cavalli-Sforza L. Biometrie Grundzuge Biologischmedizinischer Statistik 1974, Gustav Fischer Verlag, Stuttgart, pp. 171-173.
10. Cochran W.G. Estimation of bacterial densities by means of the " most probable number." Biometrics 1950, 5:105-116.
11. Blodgett R. Bacteriological analytical manual online, Appendix 2. Most probable number from serial dilutions 2006, [accessed 22.11.10]. http://www.fda.gov/Food/ScienceResearch/LaboratoryMethods/BacteriologicalAnalyticalManualBAM/ucm109656.htm.
12. SAS/C Onlinedoc 2000, SAS Institute, SAS Institute, Cary, NC.
13. Garthright W.E., Blodgett R.J. FDA's preferred MPN methods for Standard, large or unusual tests, with a spreadsheet. Food Microbiol 2003, 20:439-445.
14. Nielsen L.K., Smyth G.K., Greenfield P.F. Accuracy of the endpoint assay for virus titration. Cytotechnology 1992, 8:231-236.
15. Shay Fout G., Dahling D.R., Safferman R.S. USEPA manual of methods for virology 2001, Chapter 15, [accessed 22.11.10]. http://www.epa.gov/microbes/chapt15.pdf.
16. Hamilton M.A., Russo R.C., Thurston R.V. Trimmed Spearman-Kärber method for estimating median lethal concentrations in toxicity bioassays. Environ Sci Technol 1977, 11:714-719.